US 12,029,758 B2
Method for forming a silver-containing nanocomposite pharmaceutical compound
B. Rabindran Jermy, Dammam (SA); Vijaya Ravinayagam, Dammam (SA); and Suriya Rehman, Dammam (SA)
Assigned to Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed by Imam Abdulrahman Bin Faisal University, Dammam (SA)
Filed on Apr. 5, 2023, as Appl. No. 18/295,863.
Application 18/295,863 is a division of application No. 17/665,014, filed on Feb. 4, 2022, granted, now 11,850,260.
Prior Publication US 2023/0256013 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/38 (2006.01); A61K 33/243 (2019.01); A61K 47/02 (2006.01); A61P 31/04 (2006.01)
CPC A61K 33/38 (2013.01) [A61K 33/243 (2019.01); A61K 47/02 (2013.01); A61P 31/04 (2018.01)] 15 Claims
OG exemplary drawing
 
1. A method of forming a medicinal nanocomposite, the method comprising:
aging a reaction mixture comprising a silver source and carrier particles of a porous silicate material in a first solvent for 4 to 24 hours to form an aged mixture;
heating the aged mixture to 90 to 150° C. for 2 to 12 hours to form a first product;
calcining the first product at 350 to 650° C. for 1 to 6 hours to form a second product;
mixing the second product and a platinum-containing pharmaceutical compound in a second solvent for 2 to 12 hours at −15 to 15° C. to form the medicinal nanocomposite; and
isolating the medicinal nanocomposite;
wherein the medicinal nanocomposite comprises:
80 to 99 wt. % of the carrier particles of the porous silicate material selected from the group consisting of mesoporous silica, silicalite, mesosilicalite, silver-incorporated silicalite, and silver-incorporated mesosilicalite, the carrier particles of the porous silicate material having a pore framework;
0.5 to 10 wt. % of silver nanoparticles (Ag NPs) dispersed on and in the pore framework, wherein the silver nanoparticles are distinct from silver present in the silver-incorporated silicalite and/or the silver-incorporated mesosilicalite; and
0.5 to 10 wt. % of the platinum-containing pharmaceutical compound disposed on at least one surface selected from an interior pore surface of the carrier particles, an exterior surface of the carrier particles, and a surface of the silver nanoparticles,
wherein the medicinal nanocomposite releases less than 10 mol. % of the platinum-containing pharmaceutical compound after 60 to 84 hours at a pH of 4.5 to 7, based on an initial amount of the platinum-containing pharmaceutical compound present in the medicinal nanocomposite.